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bjectives This study aimed to characterize myocardial infarction after percutaneous coronary in-
ervention (PCI) based on cardiac marker elevation as recommended by the new universal deﬁnition
nd on the detection of late gadolinium enhancement (LGE) by cardiovascular magnetic resonance
CMR). It is also assessed whether baseline inﬂammatory biomarkers are higher in patients develop-
ng myocardial injury.
ackground Cardiovascular magnetic resonance accurately assesses infarct size. Baseline C-reactive
rotein (CRP) and neopterin predict prognosis after stent implantation.
ethods Consecutive patients with baseline troponin (Tn) I within normal limits and no LGE in the
arget vessel underwent baseline and post-PCI CMR. The Tn-I was measured until 24 h after PCI. Se-
um high-sensitivity CRP and neopterin were assessed before coronary angiography.
esults Of 45 patients, 64 (53 to 72) years of age, 33% developed LGE with infarct size of 0.83 g
interquartile range: 0.32 to 1.30 g). A Tn-I elevation 99% upper reference limit (i.e., myocardial
ecrosis) (median Tn-I: 0.51 g/l, interquartile range: 0.16 to 1.23) and Tn-I 3 upper reference
imit (i.e., type 4a myocardial infarction [MI]) occurred in 58% and 47% patients, respectively. LGE
as undetectable in 42% and 43% of patients with periprocedural myocardial necrosis and type 4a
I, respectively. Agreement between LGE and type 4a MI was moderate (kappa  0.45). The levels
f CRP or neopterin did not signiﬁcantly differ between patients with or without myocardial injury,
etected by CMR or according to the new deﬁnition (p  NS).
onclusions This study reports the lack of substantial agreement between the new universal deﬁni-
ion and CMR for the diagnosis of small-size periprocedural myocardial damage after complex PCI.
aseline levels of CRP or neopterin were not predictive for the development of periprocedural myo-
ardial damage. (J Am Coll Cardiol Intv 2010;3:950–8) © 2010 by the American College of
ardiology Foundation
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951he new “universal” definition of myocardial infarction
MI) after percutaneous coronary interventions (PCI) is
ased on the elevation of cardiac markers 3  99th
ercentile of the upper reference limit (URL) (1,2). Car-
iovascular magnetic resonance (CMR) can directly visual-
ze areas of myocardial damage with late gadolinium en-
ancement (LGE) in all segments of the left ventricle (LV)
nd can accurately assess infarct size (3,4). Recently, high
See page 959
ose atorvastatin has been shown to reduce the incidence of
eriprocedural MI in a randomized placebo trial (5). Statins
ave been shown to reduce the levels of C-reactive protein
CRP) and exert an anti-inflammatory effect (6,7). Several
tudies have shown that baseline elevated inflammatory
iomarkers, such as CRP and neopterin—a marker of
acrophage activity—predict adverse clinical events follow-
ng PCI (8–12). To date, it is unknown whether the
ccurrence of periprocedural myocardial damage according
o the new universal definition is paralleled by the develop-
ent of LGE on CMR. We therefore aimed to report the
ncidence of periprocedural myocardial damage according to
he new definition and as LGE detected by CMR, further
ssessing the extent of infarcts, their effect on LV function,
nd their predictors. We also investigated whether patients
ho develop periprocedural myocardial damage have ele-
ated levels of baseline CRP and neopterin.
ethods
thics. This study was performed according to the princi-
les of the Declaration of Helsinki and was approved by the
oyal Brompton Hospital National Health Service institu-
ional ethics committee. Each patient gave written informed
onsent.
atient population. Between December 2005 and April
008, 45 consecutive patients undergoing complex PCI,
ith either stable or unstable angina were prospectively
nrolled. Unstable angina was classified according to Braun-
ald classification (13). Patients with class I to III B were
nrolled. Stable angina was classified as chest pain on
xertion with a stable pattern for at least the last 6 months
receding the admission. All patients with baseline eleva-
ion of troponin I (Tn-I) above the upper limit of normal of
.04 g/l or of creatine kinase-myocardial band (CK-MB)
evels above the upper limit of normal of 5.9 g/l were
xcluded. Additional exclusion criteria were previous docu-
ented MI or presence of LGE in the territory of the vessel
argeted for intervention, previous revascularization of the
ulprit lesion by PCI or coronary artery bypass graft and
ontraindications to CMR. Patient clinical characteristics sre shown in Table 1; baseline angiographic and procedural
haracteristics (CMR vessel analysis) are shown in Table 2.
reatment and procedures. The PCI was performed with
tandard techniques via a femoral or radial approach, with
- or 7-F sheaths. Patients not preloaded with oral aspirin
nd clopidogrel received, as is standard practice in our
nstitution, a loading dose of intravenous aspirin 300 mg
nd clopidogrel 300 mg (if given 6 h before PCI) or 600
g (if given 6 h before PCI). Intravenous heparin (70 to
00 UI/kg body weight at the operator’s discretion) was
dministered before PCI with subsequent boluses aiming at
chieving an activating clotting time (ACT) between 250
nd 300 s. Abciximab was administered electively or as a
ail-out for slow flow at the
perator’s discretion.
MR protocol. The CMR scans
ere performed with a 1.5-T
canner (Siemens Avanto, Er-
angen, Germany) with the use
f an 8-channel phased array
ardiac coil. Eligible patients
nderwent CMR within 48 h of
heir procedure and 12 to 48 h
fter PCI. Cine images were ob-
ained with a steady-state free-
recession sequence in 2 long-
xis and multiple consecutive
hort-axis views encompassing
he LV from base to apex. Typ-
cal image parameters were: echo
ime  1.6 ms, repetition time 
.2 ms, time/cine frame 51 ms,
lpha  60 degrees, matrix 
56  256, slice thickness  8
m, gap  2 mm (14). The
GE images were acquired 10
o 15 min after intravenous in-
ection of 0.1 mmol/kg body
eight gadolinium- diethylene-
riamine penta-acetic acid in the
dentical long- and short-axis
lanes with a segmented inversion recovery gradient echo
equence (repetition time  600 ms, echo time  3.8 ms,
lpha 25 degrees, slice thickness 8 mm, gap 2 mm, typical
ixel size  1.7  1.4 mm) (15). The inversion time was
rogressively optimized and adjusted to adequately null
ormal myocardium (typical values 320 to 440 ms). The
GE images were phase-swapped to exclude artefact.
MR analysis. All CMR studies were analyzed offline with
dedicated workstation with semi-automated software
CMRTools, Cardiovascular Solutions, London, United
ingdom). All measurements were performed by 2 experi-
nced readers (A.G. and C.B-D.), blinded to whether the
Abbreviations
and Acronyms
AUC  area under the
(receiver operating
characteristics) curve
BC  bias corrected
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
CRP  C-reactive protein
hs-CRP  high-sensitivity
C-reactive protein
IQR  interquartile range
LGE  late gadolinium
enhancement
LV  left ventricle
LVEF  left ventricular
ejection fraction
TIMI  Thrombolysis In
Myocardial Infarction
TMPG  Thrombolysis In
Myocardial Infarction
perfusion myocardial grade
Tn-I  Troponin-I
URL  upper reference limitcan was before or after PCI and to the PCI results except
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952or the knowledge of the treated artery. Baseline and
ost-procedural quantitative left ventricular ejection fraction
LVEF) and end-diastolic and end-systolic volumes were
alculated from the short-axis views excluding the papillary
uscles. Evaluation of location of LGE was performed
ccording to the 17 myocardial segment classification rela-
ive to the specific coronary artery territory of distribution
16). New myocardial damage was manually traced and
alculated from the short-axis images, and it was defined as
rea of LGE with signal intensity 2 SDs compared with
emote myocardium. This area of new myocardial scar is
hen expressed in grams (assuming 1.05 g/ml as the specific
ravity of the myocardium). The occurrence of myocardial
amage was defined as the detection of new LGE areas
ompared with baseline and was classified as “adjacent”
hen it was in segments located in the same short-axis
ection where the stent was positioned or “distal” (Fig. 1)
hen it was at least 10 mm (one short-axis frame away)
rom the stent section (corresponding to 10 mm) (8).
Table 1. Patient Characteristics
All
(n  45)
No LGE
(n  30)
Any LGE
(n  15) p Value
Age, yrs 64 (53–72) 65 (56–73) 56 (44–69) 0.04
Male 33 (73) 21 (30 12 (80) 0.72
Diabetes mellitus 7 (15) 5 (16) 2 (13) 1
Hypertension 30 (66) 21 (70) 9 (21) 0.50
Smoking 9 (20) 4 (13) 5 (33) 0.14
Hypercholesterolemia 37 (82) 25 (83) 12 (80) 1
Family history of IHD 27 (60) 18 (60) 9 (60) 1
Unstable syndrome 7 (15) 4 (13) 3 (20) 0.67
Previous PCI 10 (22) 7 (23) 3 (20) 1
Previous CABG 0 (0) 0 (0) 0 (0) 1
LVEF (%), mean  SD 70 10 69 11 70 7 0.71
Multiple lesions treated 16 (35) 10 (33) 6 (40) 0.66
Multiple vessels treated 6 (13) 3 (10) 3 (20) 0.38
All values given as n (%) unless otherwise indicated. Continuous values are presented asmean
SD, or median (interquartile range) as appropriate.
CABG  coronary artery bypass graft; IHD  ischemic heart disease; LGE  late gadolinium
enhancement; LVEF  left ventricular ejection fraction; PCI  percutaneous coronary interven-
tion.
Table 2. Post-PCI Biomarkers Elevation and Agreement With LGE
Any Elevation
>99% URL
Tn-I, n (%) 26 (58)
CK-MB, n (%) 13 (29)
Tn-I, g/l, median (range) 0.51 (0.16–1.23) 0.
CK-MB, g/l, median (range) 12.5 (10.5–20.0) 22
LGE,  Cohen’s Tn-I CK-MB Tn
0.55 0.59 0.4CK-MB creatine kinase-myocardial band; LGE late gadolinium enhancement; MImyocardial infarctingiographic analyses. Angiographic analyses were per-
ormed by an experienced reader blinded to CMR results
GF). The Thrombolysis In Myocardial Infarction (TIMI)
ow grade (17), corrected TIMI frame count (18), and
IMI perfusion myocardial grade (TMPG) (19) were
valuated. These parameters were assessed before and after
CI and after each phase of the angioplasty (pre-dilation,
tenting, post-dilation) when corresponding cine runs were
vailable. Impairment of flow was defined as the reduction
f TIMI flow or TMPG during any phase of the angio-
lasty procedure, including transient reductions of at least 1
rade, or the achievement of a final TIMI 3 or TMPG
3. Quantitative coronary angiography was performed with
alidated software (Medis Medical Imaging Systems, Lei-
en, the Netherlands); the following parameters were mea-
ured: minimal luminal diameter, reference diameter, lesion
ength, and stenosis percentage.
iochemical measurements. The Tn-I and CK-MB were
ssessed at baseline and every 6 h after the procedure until
4 h time or until a trend to reducing levels was detected
nd peak value of each biomarker was considered for the
nalysis. The upper limit of normality, which corresponds to
he 99% percentile URL, was 0.04 g/l for Tn-I and 5.9
g/l for CK-MB. According to previous definition (1,2),
he elevation of Tn-I or CK-MB above the 99% percentile
RL after PCI was classified as periprocedural myocardial
ecrosis, and elevations above 3 times the 99% percentile
RL were defined as periprocedural MI (4a type). We also
eport elevation in Tn-I above 1 g/l, a cutoff used in a
revious study (4). Baseline high-sensitivity (hs) CRP and
eopterin measurements were performed 6 to 12 h before
CI. The hs-CRP was measured with COBAS Integra
Roche Diagnostics Limited, Lewes, East Sussex, United
ingdom). The CRP-Latex assay was used in both the
igh-sensitivity application (analytical range 0.2 to 12 mg/l)
nd the normal application (analytical range 2 to 160 mg/l).
nalytical precision of the hs-CRP-Latex assay was 7.6% at
level of 1.02 mg/l, 3.3% at 1.79 mg/l, and 1.3% at a level
f 4.36 mg/l. Samples outside the analytical range of the
s-CRP-Latex assay were analyzed by the CRP-Latex assay
n the normal application. The analytical precision of the
a MI Tn-I >1 g/l
Elevation
>99% and <3 URL
8 (18) 5 (11)
8 (18)
0–1.69) 1.73 (1.46–2.22) 0.08 (0.07–0.09)
0–40.0) 11.3 (9.7–12.55)
B Tn-I Tn-I CK-MB
0.38 0.16 0.49Type 4
21 (47)
5 (11)
76 (0.3
.7 (20.
-I CK-M
5 0.16on; Tn-I troponin I; URL upper reference limit.
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953ormal CRP-Latex assay was 2.4% at a level of 29.5 mg/l
nd 1.3% at a level of 113 mg/l. Neopterin serum concen-
ration was measured with a commercially available immu-
oassay (enzyme-linked immunosorbent assay kit, IBL,
amburg, Germany). The limit of detection was 1.5
mol/l. The analytic precision of the assay was 3% at the
evel of 7.7 nmol/l and 4% at the level of 20 nmol/l.
tatistical analysis. Distribution of continuous variables was
ssessed by visual estimation of frequency histograms and
ith the use of the Shapiro-Wilk test. Continuous variables
hat followed a normal distribution were described by
ean  SD, and those showing a non-normal distribution
ere described by median and interquartile range (IQR);
omparisons among 3 groups were performed with Kruskal
allis test, due to the presence of non-normal distribution
f variables; Mann Whitney U test or unpaired t test were
sed as appropriate for the comparison between 2 groups.
ates were compared by chi-square test or Fisher exact test,
s appropriate. The agreement between the presence of
GE and periprocedural damage assessed by biomarkers
as assessed using Cohen’s kappa (), where 0.0 to 0.20
ndicates slight agreement, 0.21 to 0.40 fair, 0.41 to 0.60
oderate, 0.61 to 0.80 substantial, and 0.81 to 1.00 good
greement. The relation between myocardial grams of LGE
nd Tn-I or CK-MB blood levels after PCI was assessed
ith the Spearman’s rank test, because the linearity assump-
ions between these variables were not met; the significance
f the difference between these 2 correlation coefficients was
ssessed with a t test for the comparison of 2 dependent
orrelations from the same sample (20). The diagnostic
ccuracy of post-PCI Tn-I and CK-MB levels to identify
ew LGE areas was assessed with the use of receiver
perating characteristics curves, with the calculation of the
rea under the curve (AUC) and its 95% confidence interval
CI). Bootstrap estimation of the 95% CI of the AUC was
Figure 1. Cardiac Magnetic Resonance Example of Distal Embolization Aft
(A) Short-axis view, (B) 4-chamber view. Distal embolization illustrated by latelso performed with the bias corrected (BC) method after,000 replications. The LVEF data were analyzed with
ixed effect linear regression with time (baseline and
ost-PCI) and group (identifying LGE, periprocedural
yocardial necrosis, and type 4a MI) and the interaction
etween them as fixed effects and patient and group as
andom effects (random intercept and coefficient, respec-
ively). Previous studies (21,22) reported an incidence of
ost-PCI LGE damage ranging from 23% of vessels ana-
yzed to 63% of patients enrolled, in study populations of 52
nd 40 patients, respectively. To achieve a comparable
ample size in our study, we enrolled 45 patients, estimating
cutaneous Coronary Intervention
inium enhancement (white arrows).
Figure 2. Correlation Between Infarct Grams Assessed as LGE and Tn-I
Levels After PCI
Blue circles represent patients without late gadolinium enhancement
(LGE); black squares represent patients developing adjacent LGE; and red
triangles represent patients with distal LGE. The Y axis has been modiﬁed
with a break between 2 and 7.5, due to the presence of an outlier. Tn-I er Pertroponin I; PCI  percutaneous coronary intervention.
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954n expected incidence of post-PCI LGE damage of 30%. A
-tailed p value 0.05 was the level of statistical signifi-
ance. The STATA version 10.1 (Statacorp, LP, College
tation, Texas) statistical software was used.
esults
ncidence and extent of periprocedural myocardial damage.
ew areas of LGE after PCI developed in 15 of 45 (33.3%)
atients, with a median infarct size of 0.83 g (IQR 0.32 to
.30) corresponding to 0.53% (IQR 0.41% to 1.05%) of
otal LV mass. Of note, infarct size was 1.5% of total LV
ass in 14 of 15 patients, with only 1 patient developing a
eriprocedural infarct corresponding to 8% of total LV
ass. Distal new LGE areas occurred in 8 of 15 patients
53.3%) and adjacent LGE in 7 of 15 (46.7%) with an
nfarct size of 0.47 g (IQR 0.22 to 0.94 g) versus 0.96 g
IQR 0.60 to 1.43 g, respectively, p  0.1). Patients who
eveloped new LGE were younger (Table 1) with no other
ifference in baseline clinical characteristics. Post-PCI Tn-I
nd CK-MB values are reported in Table 2. Of note, new
GE areas were not detectable in 42% (11 of 26) and in
3% (3 of 13) of patients with periprocedural myocardial
ecrosis defined as Tn-I or CK-MB elevations, respectively,
n 43% (9 of 21) and 40% (2 of 5) of patients with type 4a
I, defined as Tn-I or CK-MB elevations, respectively,
Figure 3. Correlation Between Infarct Grams Assessed as LGE and CK-MB
Levels After PCI
Blue circles represent patients without LGE; black squares represent
patients developing adjacent LGE; and red triangles represent patients
with distal LGE. The Y axis has been modiﬁed with a break between 2 and
7.5, due to the presence of an outlier. CK-MB: creatine kinase-myocardial
band isoenzyme; other abbreviations as in Figure 2.nd in 25% (2 of 8) of patients with Tn-I rise 1 g/l.All patients with LGE elevation had periprocedural
yocardial necrosis defined as Tn-I elevation.
The agreement of LGE with Tn-I and CK-MB was
ever substantial (Table 2). Grams of new LGE correlated
ith Tn-I levels after PCI, r  0.64, p  0.0001, and with
K-MB levels, r  0.55, p  0.0001 (p  0.17 for the
omparison between the 2 correlations) (Figs. 2 and 3). The
UC derived from receiver operating characteristics curves
nalysis for the prediction of new LGE was 0.85 (95% CI:
.74 to 0.96; BC 95% CI: 0.72 to 0.94) for Tn-I levels and
.79 (95% CI: 0.65 to 0.94; BC 95% CI: 0.63 to 0.92) for
K-MB (p  0.22 for the comparison between AUC)
Fig. 4).
ffect of PCI and periprocedural myocardial damage on
VEF. The change in LVEF from baseline after PCI was
ot statistically significant (2.14%, 95% CI: 4.7 to 0.43,
 0.10). The occurrence of periprocedural damage did not
ignificantly affect LEVF change between baseline and after
CI (LGE: 3.27%, 95% CI: 8.59 to 2.02, p  0.23);
eriprocedural necrosis Tn-I (2.32, 95% CI: 7.44 to
.79, p  0.37); periprocedural necrosis CK-MB (2.78%,
5% CI: 8.30 to 2.75, p  0.32); type 4a MI Tn-I
4.23%, 95% CI: 9.21 to 0.76, p  0.09); type 4a MI
K-MB (1.06%, 95% CI: 6.93 to 9.06, p  0.79); Tn-I
g/l (0.67%, 95% CI: 6.54 to 5.21, p  0.82).
Figure 4. Receiver Operating Characteristic Curve Describing the Ability
of Troponin-I and Post-CK-MB to Correctly Classify Patients Developing
Late Gadolinium Enhancement
Troponin-I (blue line) and after creatine kinase-myocardial band (CK-MB)
(red line). The area under the curve was 0.85, (bias corrected 95% conﬁ-
dence interval: 0.72 to 0.94) for troponin I and 0.79 (bias corrected 95%
conﬁdence interval: 0.63 to 0.92) for after CK-MB; p  0.22 for the compari-
son between the 2 markers.
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955redictors of periprocedural myocardial damage. Angio-
raphic analysis was performed on 52 CMR territories,
ncluding 2 vessels treated in 6 patients and a very large
rst diagonal of a bifurcation lesion (Table 3). Because
erial lesions were present in 5 vessels, 57 lesions in total
ere considered. New LGE areas were detected in the
erritory distribution of 15 of 52 (23%) vessels. Among
aseline angiographic and procedural characteristics,
ost-dilation was more frequent in the group developing
ew LGE areas compared with the other group (100% vs.
3%, p  0.046). Final angiographic indexes of myocar-
ial perfusion did not significantly differ between groups
Table 3).
nﬂammation and periprocedural damage. The levels of
RP and of neopterin were not significantly different in
atients developing LGE as compared with the remaining
CRP: 5.0 mg/l [IQR 1.0 to 8.1] vs. 2.51 mg/l [IQR 1.3 to
Table 3. Baseline Angiographic and Procedural Chara
Vessels
(n  52)
Bifurcation 18 (35)
CTO 5 (9)
Treated vessel
LAD 26 (50)
LCX* 11 (21)
RCA 15 (29)
Ambrose B2-C type 30 (57)
Total stent length, mm 22 (15–32)
Number of stents
0 1 (2)
1 34 (65)
2 12 (23)
3 4 (8)
4 1 (2)
DES use 34 (65)
Pre-dilation 43 (83)
Post-dilation 42 (81)
Max pressure inﬂation, atm 16.3 3.5
Max balloon diameter, mm 3.2 0.48
QCA measurement
MLD pre, mm 0.63 (0.4–0.97)
Stenosis severity, % 68.3 17.5
Stenosis length, mm 9.6 (8.1–14.1)
Final TIMI ﬂow grade 3 49 (94)
Final TMPG 3 39 (75)
Flow impairment 20 (38)
Final cTFC, median (range)
Cardiovascular magnetic resonance (CMR) vessel analysis. All values g
the vessel treated corresponding to the CMR left circumflex artery (
(interquartile range) as appropriate.
cTFC correctedThrombolysis InMyocardial Infarction framecount
descending artery; LGE  late gadolinium enhancement; MLD  micoronary artery; TIMI Thrombolysis In Myocardial Infarction; TMPG Throm.4], p  0.72; neopterin: 6.6 nmol/l [IQR 4.9 to 7.7] vs.
.5 nmol/l [IQR 4.4 to 9.5], p  0.46). When considering
groups—patients with distal LGE, adjacent LGE, and no
GE—there was no significant difference in the levels of
RP (7.4 mg/l [IQR 2.5 to 61.9], 2.2 mg/l [IQR 0.9 to
.3], 2.5 mg/l [IQR 1.3 to 7.4], respectively, p  0.15) or
eopterin (7.1 nmol/l [IQR 6.1 to 8.3], 4.9 nmol/l [IQR 4.4
o 9.0], 6.5 nmol/l [IQR 4.4 to 9.5], respectively, p 0.18).
able 4 reports baseline levels of CRP and neopterin
ccording to periprocedural myocardial damage. No signif-
cant difference was found between groups.
iscussion
his study reports the lack of substantial agreement be-
ween the new universal definition (1,2) and CMR for the
tics
No LGE
(n  37)
Any LGE
(n  15) p Value
12 (32) 6 (40) 0.65
4 (11) 1 (6) 1
0.40
19 (51) 7 (47)
6 (16) 5 (33)
12 (32) 3 (20)
21 (57) 9 (60) 0.91
20 (14–32) 23 (16–28) 0.86
0.48
0 (0) 1 (7)
25 (68) 9 (60)
9 (24) 3 (20)
2 (5) 2 (13)
1 (3) 0 (0)
25 (68) 9 (60) 0.60
30 (81) 13 (87) 1
27 (73) 15 (100) 0.046
16.1 3.5 17.0 3.4 0.37
3.2 0.45 3.2 0.56 0.77
.66 (0.4–1.2) 0.62 (0.4–0.7) 0.53
67.5 17.9 70.6 16.3 0.54
9.9 (8.2–14.1) 9.4 (7–14.4) 0.66
34 (92) 15 (100) 0.55
27 (73) 12 (80) 0.73
15 (41) 5 (33) 0.76
10 (7–13) 8.5 (6–11) 0.42
(%) unless otherwise indicated. *A large anatomic first diagonal was
rritory. Continuous values are presented as mean  SD, or median
chronic total occlusions; DESdrug-eluting stent; LAD left anterior
men diameter; QCA  quantitative coronary analysis; RCA  rightcteris
0
iven as n
LCX) te
; CTO
nimal lubolysis In Myocardial Infarction myocardial perfusion grade.
d
m
s
i
fi
p
s
p
s
i
a
m
L
g
i
g
l
s
l
(
b
d
i
p
o
l
m
g
h
a
i
c
s
i
s
a
p
f
o
w
p
s
p
e
n
(
t
w
o
p
d
h
o
p
c
n
l
w
a
b
w
s
s
c
m
a
m
i
u
l
S
s
c
s
s
c
d
h
n
l
D
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 9 , 2 0 1 0
S E P T E M B E R 2 0 1 0 : 9 5 0 – 8
Locca et al.
New Definition of MI After PCI
956iagnosis of periprocedural myocardial damage. Further-
ore, it shows that the size of periprocedural damage is
mall, regardless of the definition used, with no significant
mpairment in LVEF in the acute phase. Finally, it identi-
es procedural factors, such as the use of post-dilation, as
otential contributors to LGE, but could not demonstrate a
ignificant elevation in baseline CRP or neopterin levels in
atients developing periprocedural myocardial damage.
In our study, infarcts were much smaller than previous
tudies (3,4) and were below the threshold of 1 g/l of Tn-I
n the vast majority of cases. The absence of substantial
greement (0.61) between biochemical assays and CMR
ight depend in part on the higher sensitivity threshold of
GE, due to partial volume effects and the use of a 2-mm
ap between the 8-mm-thick inversion-recovery slices that
ncreases the risk for some LGE to be confined to the 2-mm
ap, and the use of different assays of Tn-I with an upper
imit of normality 25 times smaller than that in the previous
tudy (4). Furthermore, distal micro-embolization usually
eads to multiple micro-infarcts with patchy distribution
23). Any such micro-infarct might not be large enough to
e detected by LGE, but the cumulative necrosis can be
etected by Tn-I and CK-MB, therefore accounting for the
mbalance in sensitivity of LGE relative to Tn-I in the
resent study. However, troponin release has been shown to
ccur also without irreversible myocardial damage in ath-
etes after a marathon, as a consequence of enhanced
yocyte membrane permeability because of increased oxy-
en radical production (24). Cardiac embolization damage
as been shown to be worsened by oxygen radicals in an
nimal model (25). Therefore, in the setting of a small
Table 4. Inflammatory Biomarkers and Periprocedural Damage
CRP, mg/l p Value Neopterin, nmol/l p Value
PP necrosis (Tn-I) 0.61 0.81
Yes 4.3 (1.3–8.1) 7.1 (5.0–8.7)
No 2.4 (1.5–6.0) 6.0 (4.4–9.7)
4a MI (Tn-I) 4.5 (0.8–8.1) 0.82 6.6 (4.9–9.0) 0.92
Yes 2.5 (1.5–6.0) 6.5 (4.7–9.0)
No
Tn-I 1 g/l
Yes 2.9 (1.3–6.3) 0.59 7.1 (3.4–9.0) 0.63
No 4.2 (1.3–8.1) 6.5 (4.9–9.0)
PP necrosis (CK-MB) 0.94 0.79
Yes 4.0 (1.3–8.1) 7.7(4.9–9.0)
No 2.5 (1.3–7.4) 6.1 (4.7–9.0)
4a MI (CK-MB) 0.68 0.74
Yes 2.9 (1.7–5.0) 8.6 (5.7–9.1)
No 4.2 (0.9–8.1) 6.1 (4.7–9.0)
CK-MB creatine kinase-myocardial band; CRP C-reactive protein; MImyocardial infarction;
PP periprocedural; Tn-I troponin I.ncrease in myocardial enzymes, as in our study, the risk that tardiac markers might falsely detect irreversible damage
hould be considered.
The impact of troponin elevation after PCI has been
nvestigated by recent meta-analyses (26,27) that have
hown that both troponin elevation and type 4a MI are
ssociated with increased risk of major adverse cardiac end
oints and of mortality, both in-hospital and at 18-month
ollow-up. We did not address the clinical prognostic value
f myocardial damage at follow-up; thus we cannot verify
hether elevation in cardiac markers show a differential
rognostic impact as compared with LGE.
The presence of small sized infarcts and the absence of
ignificant LVEF impairment from baseline in the acute
hase of PCI, due to periprocedural myocardial damage, are
ncouraging; however, recent studies have documented a
egative prognostic value of LGE independently of its size
28,29). Factors that might have played a role in minimizing
he extent of periprocedural myocardial damage in our study
ere the systematic wiring of side branches to avoid
cclusion and appropriate stent selection. We found that the
revalence of post-dilation was higher among patients who
eveloped LGE, suggesting that post-dilation might en-
ance plaque fragmentation with downstream embolization
r facilitate side branch occlusion. It is also plausible that
ost-dilation might cause stent overexpansion in some
ases, a factor that has been shown to be associated with
o-reflow phenomenon in the setting of acute MI (30).
We could not detect a significant difference in baseline
evels of CRP and neopterin between patients with or
ithout myocardial damage. However, the small sample size
nd the absence of prospective selection of patients on the
asis of high versus low levels of inflammatory biomarkers
ith a cutoff might have played a role for the absence of
ignificant results. The detection of higher, albeit not
ignificant levels of CRP in patients with distal LGE as
ompared with adjacent LGE and those without LGE
ight deserve further investigation in larger studies, because
pathophysiological rationale underlying such association
ight be an enhanced microcirculatory vulnerability or
ncreased coronary plaque susceptibility to embolization
pon balloon or stent manipulation in patients with higher
evels of CRP (31).
tudy limitations. The main limitation is the small sample
ize. The use of a CMR 3-dimensional pulse sequence with
omplete coverage of the entire LV or a 2-dimensional pulse
equence with thin slices (6 or 7 mm) and no gap, a more
ensitive imaging sequence, and a higher dose of MR
ontrast (i.e., 0.20 mmol/kg body weight gadolinium-
iethylenetriamine penta-acetic acid) might have lead to a
igher correlation between CMR LGE and biomarkers of
ecrosis. We did not assess the size and number of embo-
izing particles, because we did not perform intracoronary
oppler recording of embolizing events. It is possible thathe incidence of distal embolization was lower in this study,
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957ecause PCI of vein grafts and patients with unstable angina
ith positive troponin were excluded.
onclusions
his study reports the lack of substantial agreement be-
ween myocardial infarction biomarker changes and CMR
or the diagnosis of small-sized periprocedural myocardial
amage after complex PCI. Myocardial damage, indepen-
ently of the definition used, is of small size and does not
ignificantly affect LVEF in the early phase after PCI.
inally, this study suggests that post-dilation might be a
ontributing factor to LGE and shows that baseline levels of
RP and neopterin are not significantly higher in patients
ho develop periprocedural myocardial damage.
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